Up-to-date role of biologics in the management of respiratory syncytial virus

References

• Karron RA, Black RE. Determining the burden of respiratory syncytial virus disease: the known and the unknown. Lancet. 2017 Sep 2;390(10098):917–918.
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1545–1555.
   PubMed Web of Science ®Google Scholar
• Nokso-Koivisto J, Marom T, Chonmaitree T. Importance of viruses in acute otitis media. Curr Opin Pediatr. 2015 Feb;27(1):110–115.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):1749–1759.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5;360(6):588–598.
   PubMed Web of Science ®Google Scholar
• Blanco JC, Boukhvalova MS, Shirey KA, et al. New insights for development of a safe and protective RSV vaccine. Hum Vaccin. 2010 6; Jun(6): 482–492 .
   Google Scholar
• Buchholz UJ, Cunningham CK, Muresan P, et al. Live Respiratory Syncytial Virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. J Infect Dis. 2018 Apr 11;217(9):1338–1346.
   PubMed Web of Science ®Google Scholar
• McFarland EJ, Karron RA, Muresan P, et al. Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is Highly Immunogenic In Children. J Infect Dis. 2018 Apr 11;217(9):1347–1355.
   PubMed Web of Science ®Google Scholar
• Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013;372:259–284.
   PubMed Web of Science ®Google Scholar
• Clark CM, Guerrero-Plata A. Respiratory syncytial virus vaccine approaches: a current overview. Curr Clin Microbiol Rep. 2017 Dec;4(4):202–207.
   PubMed Web of Science ®Google Scholar
• Al-Halifa S, Gauthier L, Arpin D, et al. Nanoparticle-based vaccines against respiratory viruses. Front Immunol. 2019;10:22.
   PubMed Web of Science ®Google Scholar
• Smith TRF, Schultheis K, Broderick KE. Nucleic acid-based vaccines targeting respiratory syncytial virus: delivering the goods. Hum Vaccin Immunother. 2017 Nov 2;13(11):2626–2629.
   PubMed Web of Science ®Google Scholar
• Chin J, Magoffin RL, Shearer LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969 Apr;89(4):449–463 .
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969 Apr;89(4):422–434 .
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969 Apr;89(4):435–448.
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969 Apr;89(4):405–421 .
   PubMed Web of Science ®Google Scholar
• Murphy BR, Prince GA, Walsh EE, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol. 1986 Aug;24(2):197–202 .
   PubMed Web of Science ®Google Scholar
• Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol. 1988 Aug;26(8):1595–1597.
   PubMed Web of Science ®Google Scholar
• Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999 Nov;5(4):285–294.
   PubMed Web of Science ®Google Scholar
• Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development - A global agenda. Vaccine. 2016 Jun 3;34(26):2870–2875.
   PubMed Web of Science ®Google Scholar
• Openshaw PJM, Chiu C, Culley FJ, et al. Protective and Harmful Immunity to RSV Infection. Annu Rev Immunol. 2017 Apr;26(35):501–532 .
   Google Scholar
• Malloy AM, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:211–231.
   PubMed Web of Science ®Google Scholar
• Graham BS. Immunological goals for respiratory syncytial virus vaccine development. Curr Opin Immunol. 2019 Aug;59:57–64.
   PubMed Web of Science ®Google Scholar
• Gilman MS, Castellanos CA, Chen M, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol. 2016 Dec 16;1(6):eaaj1879-eaaj1879.
   PubMed Web of Science ®Google Scholar
• Tian D, Battles MB, Moin SM, et al. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun. 2017 Nov 30;8(1):1877.
   PubMedGoogle Scholar
• McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (New York, NY). 2013 Nov 1;342(6158):592–598.
   Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (New York, NY). 2013 May 31;340(6136):1113–1117.
   Google Scholar
• Habibi MS, Jozwik A, Makris S, et al. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015 May 1;191(9):1040–1049.
   PubMed Web of Science ®Google Scholar
• Crank MC, Ruckwardt TJ, Chen M, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science (New York, NY). 2019 Aug 2;365(6452):505–509.
   Google Scholar
• Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018 Oct;18(10):e295–e311 .
   PubMed Web of Science ®Google Scholar
• Fries L, Shinde V, Stoddard JJ, et al. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. Immun ageing. 2017;14(1):8 .
   PubMedGoogle Scholar
• August A, Glenn GM, Kpamegan E, et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017 Jun 27;35(30):3749–3759.
   PubMed Web of Science ®Google Scholar
• Simoes EA, Tan DH, Ohlsson A, et al. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine. 2001 Dec 12;20(5–6):954–960.
   PubMed Web of Science ®Google Scholar
• Marcandalli J, Fiala B, Ols S, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell. 2019 Mar 7;176(6):1420–1431.e17.
   PubMed Web of Science ®Google Scholar
• Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 1997 Apr 14;230(2):155–166.
   PubMed Web of Science ®Google Scholar
• Corvaia N, Tournier P, Nguyen TN, et al. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. J Infect Dis. 1997 Sep;176(3):560–569.
   PubMed Web of Science ®Google Scholar
• Plotnicky-Gilquin H, Huss T, Aubry JP, et al. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology. 1999 May 25;258(1):128–140.
   PubMed Web of Science ®Google Scholar
• Power UF, Huss T, Michaud V, et al. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. J Virol. 2001 Dec;75(24):12421–12430.
   PubMed Web of Science ®Google Scholar
• Plotnicky H, Siegrist C-A, Aubry J-P, et al. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. Vaccine. 2003 Jun 2;21(19–20):2651–2660.
   PubMed Web of Science ®Google Scholar
• Siegrist CA, Plotnicky-Gilquin H, Cordova M, et al. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J Infect Dis. 1999 Jun;179(6):1326–1333.
   PubMed Web of Science ®Google Scholar
• Power UF, Nguyen TN, Rietveld E, et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis. 2001 Dec 1;184(11):1456–1460.
   PubMed Web of Science ®Google Scholar
• de Waal L, Power UF, Yuksel S, et al. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine. 2004 Feb 25;22(8):915–922.
   PubMed Web of Science ®Google Scholar
• Fuentes S, Coyle EM, Golding H, et al. Nonglycosylated G-protein vaccine protects against homologous and heterologous Respiratory Syncytial Virus (RSV) challenge, while glycosylated G enhances RSV lung pathology and cytokine levels. J Virol. 2015 Aug;89(16):8193–8205.
   PubMed Web of Science ®Google Scholar
• Lee J, Klenow L, Coyle EM, et al. Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains. PLoS Pathog. 2018 Aug;14(8):e1007262.
   PubMed Web of Science ®Google Scholar
• Wathen MW, Kakuk TJ, Brideau RJ, et al. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J Infect Dis. 1991 Mar;163(3):477–482 .
   PubMed Web of Science ®Google Scholar
• Prince GA, Capiau C, Deschamps M, et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J Virol. 2000 Nov;74(22):10287–10292.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE, Capellan J, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines–nonadjuvanted vaccine or vaccine adjuvanted with alum–given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008 Nov 1;198(9):1317–1326.
   PubMed Web of Science ®Google Scholar
• Gan SW, Tan E, Lin X, et al. The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J Biol Chem. 2012 Jul 13;287(29):24671–24689.
   PubMed Web of Science ®Google Scholar
• Collins PL, Olmsted RA, Johnson PR. The small hydrophobic protein of human respiratory syncytial virus: comparison between antigenic subgroups A and B. J Gen Virol. 1990 Jul;71(Pt 7):1571–1576.
   PubMedGoogle Scholar
• Schepens B, Schotsaert M, Saelens X. Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen. Immunotherapy. 2015;7(3):203–206.
   PubMed Web of Science ®Google Scholar
• Karkada M, Weir GM, Quinton T, et al. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother. 2010 Apr;33(3):250–261
   PubMed Web of Science ®Google Scholar
• Langley JM, MacDonald LD, Weir GM, et al. A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study. J Infect Dis. 2018 Jul 2;218(3):378–387.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Malkin E, Abughali N, et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J. 2012 Feb;31(2):109–114 .
   PubMed Web of Science ®Google Scholar
• Yang CF, Wang CK, Malkin E, et al. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine. 2013 Jun 10;31(26):2822–2827.
   PubMed Web of Science ®Google Scholar
• Karron RA, Luongo C, Thumar B, et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med. 2015 Nov 4;7(312):312ra175.
   PubMed Web of Science ®Google Scholar
• Rey-Jurado E, Soto J, Galvez N, et al. A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus. Hum Vaccin Immunother. 2017 Sep 2;13(9):2092–2097.
   PubMed Web of Science ®Google Scholar
• Galvez NMS, Soto JA, Kalergis AM. New insights contributing to the development of effective vaccines and therapies to reduce the pathology caused by hRSV. Int J Mol Sci. 2017 11;18(8):Aug
   Web of Science ®Google Scholar
• Boyoglu-Barnum S, Todd SO, Meng J, et al. Mutating the CX3C Motif in the G protein should make a live respiratory syncytial virus vaccine safer and more effective. J Virol. 2017 May 15;91(10). DOI:10.1128/JVI.02059-16.
   PubMed Web of Science ®Google Scholar
• Ha B, Chirkova T, Boukhvalova MS, et al. Mutation of respiratory syncytial virus G protein’s CX3C Motif attenuates infection in cotton rats and primary human airway epithelial cells. Vaccines (Basel). 2019 Jul 19;7(3):69.
   PubMed Web of Science ®Google Scholar
• Haynes LM, Jones LP, Barskey A, et al. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol. 2003 Sep;77(18):9831–9844 .
   PubMed Web of Science ®Google Scholar
• Harcourt JL, Karron RA, Tripp RA. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis. 2004 Dec 1;190(11):1936–1940.
   PubMed Web of Science ®Google Scholar
• Zhang W, Choi Y, Haynes LM, et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol. 2010 Jan;84(2):1148–1157 .
   PubMed Web of Science ®Google Scholar
• Johnson CH, Miao C, Blanchard EG, et al. Effect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection. Comp Med. 2012 Feb;62(1):14–20.
   PubMed Web of Science ®Google Scholar
• Choi Y, Mason CS, Jones LP, et al. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol. 2012 Jun;25(3):193–203.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol. 2001 Aug;2(8):732–738.
   PubMed Web of Science ®Google Scholar
• Boyoglu-Barnum S, Gaston KA, Todd SO, et al. A respiratory syncytial virus (RSV) anti-G protein F(ab’)2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol. 2013 Oct;87(20):10955–10967.
   PubMed Web of Science ®Google Scholar
• Chirkova T, Boyoglu-Barnum S, Gaston KA, et al. Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol. 2013 Dec;87(24):13466–13479.
   PubMed Web of Science ®Google Scholar
• Boyoglu-Barnum S, Chirkova T, Todd SO, et al. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice. J Virol. 2014 Sep;88(18):10569–10583.
   PubMed Web of Science ®Google Scholar
• Chirkova T, Lin S, Oomens AG, et al. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol. 2015 Sep;96(9):2543–2556.
   PubMedGoogle Scholar
• Jorquera PA, Choi Y, Oakley KE, et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PloS One. 2013;8(9):e74905.
   PubMed Web of Science ®Google Scholar
• Jares Baglivo S, Polack FP. The long road to protect infants against severe RSV lower respiratory tract illness. F1000Res. 2019;8. pii: F1000.
   PubMedGoogle Scholar
• Gilbert SC. Clinical development of modified vaccinia virus ankara vaccines. Vaccine. 2013 Sep 6;31(39):4241–4246.
   PubMed Web of Science ®Google Scholar
• Wire B Vaxart presents positive preclinical data for oral RSV vaccine at RSV vaccines for the world conference. 2015; [Cited Nov 2019]. https://www.businesswire.com/news/home/20151119005368/en/Vaxart-Presents-Positive-Preclinical-Data-Oral-RSV
   Google Scholar
• B.V JVP. A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health. 2019; [Cited Jul 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03339713
   Google Scholar
• Cicconi P, Jones C, Sarkar E, et al. First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on ChAd155 viral vector expressing RSV viral proteins F, N and M2-1 in healthy adults. Clin Infect Dis. 2019 Jul 24. DOI:10.1093/cid/ciz653.
   PubMed Web of Science ®Google Scholar
• Novavax. New data from novavax phase 3 prepare™ trial of resVax™. Presented at 2019 IDSOG Annual Meeting, Big Sky, Montana. 2019 Aug 12.
   Google Scholar
• Novavax. Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults. 2016; [Cited Sep 2015]. https://ir.novavax.com/news-releases/news-release-details/novavax-announces-topline-rsv-f-vaccine-data-two-clinical-trials
   Google Scholar
• Ascough S, Vlachantoni I, Kalyan M, et al. Local and systemic immunity against respiratory syncytial virus induced by a novel intranasal vaccine. a randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med. 2019 Aug 15;200(4):481–492.
   PubMed Web of Science ®Google Scholar
• BV M. Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine (SynGEM). 2016 [Cited Nov 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02958540
   Google Scholar
• Aranda SS, Polack FP. Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: perspectives for the next decade. Front Immunol. 2019;10:1006.
   PubMed Web of Science ®Google Scholar
• Huffman JH, Sidwell RW, Khare GP, et al. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973 Feb;3(2):235–241 .
   PubMed Web of Science ®Google Scholar
• Sidwell RW, Huffman JH, Khare GP, et al. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science (New York, NY). 1972 Aug 25;177(4050):705–706.
   Google Scholar
• Witkowski JT, Robins RK, Sidwell RW, et al. Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem. 1972 Nov;15(11):1150–1154 .
   PubMed Web of Science ®Google Scholar
• Hruska JF, Bernstein JM, Douglas RG Jr., et al. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother. 1980 May;17(5):770–775 .
   PubMed Web of Science ®Google Scholar
• Hruska JF, Morrow PE, Suffin SC, et al. In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob Agents Chemother. 1982 Jan;21(1):125–130.
   PubMed Web of Science ®Google Scholar
• Hall CB, Walsh EE, Hruska JF, et al. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. Jama. 1983 May 20;249(19):2666–2670.
   PubMed Web of Science ®Google Scholar
• Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. New Engl J Med. 1983 Jun 16;308(24):1443–1447.
   PubMed Web of Science ®Google Scholar
• Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 1983 Nov;72(5):613–618.
   PubMed Web of Science ®Google Scholar
• Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med. 1996 Sep;150(9):942–947.
   PubMedGoogle Scholar
• McCoy D, Wong E, Kuyumjian AG, et al. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. Transplant Infect Dis. 2011 Apr;13(2):117–121.
   PubMed Web of Science ®Google Scholar
• Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: current and emerging treatment options. Clinicon Econ Outcomes Res. 2014;6:217–225.
   PubMedGoogle Scholar
• Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013 Oct;57(8):1069–1077.
   PubMed Web of Science ®Google Scholar
• Perron M, Stray K, Kinkade A, et al. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1264–1273.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014 Aug 21;371(8):711–722.
   PubMed Web of Science ®Google Scholar
• German P, Xin Y, Chien JW, et al. Phase 1 first-in-human, single- and multiple-ascending dose, and food effect studies to assess the safety, tolerability, and pharmacokinetics of presatovir for the treatment of respiratory syncytial virus infection. The Journal of Clinical Pharmacology. 2018 Apr 17;58(8):1025–1034.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Nam HH, Adams PL, et al. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv antiviral group conference. Antiviral Res. 2019 Jul;167:45–67.
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The respiratory syncytial virus immune globulin study group. New Engl J Med. 1993 Nov 18;329(21):1524–1530.
   PubMed Web of Science ®Google Scholar
• Bouthillier MJ. RespiGam/PREVENT study questioned. Pediatrics. 1997 Aug;100(2 Pt 1):275–276.
   PubMed Web of Science ®Google Scholar
• Respiratory syncytial virus immune globulin intravenous. Paediatr Child Health. 1998 Jan 3;3(1):11–14.
   PubMedGoogle Scholar
• DeVincenzo J, Tait D, Efthimiou J, et al. Human antiviral efficacy, safety and pharmacokinetics of RV521, an Inhibitor of the RSV-F protein: a randomized, placebo-controlled, respiratory syncytial virus challenge study. Antimicrob Agents Chemother. 2019 Nov 11;64(2). DOI:10.1128/AAC.01884-19.
   Web of Science ®Google Scholar
• Jordan PC, Stevens SK, Tam Y, et al. Activation pathway of a nucleoside analog inhibiting respiratory syncytial virus polymerase. ACS Chem Biol. 2017 Jan 20;12(1):83–91.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015 Nov 19;373(21):2048–2058.
   PubMed Web of Science ®Google Scholar
• Detalle L, Stohr T, Palomo C, et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother. 2016 Jan;60(1):6–13.
   PubMed Web of Science ®Google Scholar
• Larios Mora A, Detalle L, Gallup JM, et al. Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. mAbs. 2018 Jul;10(5):778–795.
   PubMed Web of Science ®Google Scholar
• Broadbent L, Parke HG, Ferguson LJ, et al. Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures. Antimicrob Agents Chemother. 2019 Nov 25;64(2). DOI:10.1128/AAC.02034-19.
   Web of Science ®Google Scholar
• Broadbent L, Parke HG, Ferguson LJ, et al. Comparative therapeutic potential of ALX-0171 and palivizumab against respiratory syncytial virus clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures. Antimicrob Agents Chemother. 2020 Jan 27;64(3). DOI:10.1128/AAC.02247-19.
   PubMedGoogle Scholar
• Alvarez R, Elbashir S, Borland T, et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother. 2009 Sep;53(9):3952–3962 .
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010 May 11;107(19):8800–8805.
   PubMed Web of Science ®Google Scholar
• Yousem SA, Duncan SR, Griffith BP. Interstitial and airspace granulation tissue reactions in lung transplant recipients. Am J Surg Pathol. 1992 Sep;16(9):877–884.
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016 Feb;35(2):213–221 .
   PubMed Web of Science ®Google Scholar
• Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011 Feb 15;183(4):531–538.
   PubMed Web of Science ®Google Scholar
• Coates M, Brookes D, Kim YI, et al. Preclinical Characterization of PC786, an inhaled small-molecule respiratory syncytial virus l protein polymerase inhibitor. Antimicrob Agents Chemother. 2017 Sep;61(9). doi:10.1128/AAC.00737-17.
   Web of Science ®Google Scholar
• Mirabelli C, Jaspers M, Boon M, et al. Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium. J Antimicrob Chemother. 2018 Jul 1;73(7):1823–1829.
   PubMed Web of Science ®Google Scholar
• Brookes DW, Coates M, Allen H, et al. Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium. Br J Pharmacol. 2018 Jun;175(12):2520–2534.
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Kusuda S, Mochizuki H, et al. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013 Nov;132(5):811–818.
   PubMed Web of Science ®Google Scholar
• Santos RP, Chao J, Nepo AG, et al. The use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia. Pediatrics. 2012 Dec;130(6):e1695–9.
   PubMed Web of Science ®Google Scholar
• Lagos R, DeVincenzo JP, Munoz A, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J. 2009 Sep;28(9):835–837.
   PubMed Web of Science ®Google Scholar
• Regeneron. Regeneron to discontinue development of suptavumab for respiratory syncytial virus 2017,Aug 17. Available from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-discontinue-development-suptavumab-respiratory?releaseid=1037184
   Google Scholar
• Griffin MP, Khan AA, Esser MT, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion f-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017 Mar;61(3). DOI:10.1128/AAC.01714-16.
   Web of Science ®Google Scholar
• Domachowske JB, Khan AA, Esser MT, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion f-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018 Sep;37(9):886–892.
   PubMed Web of Science ®Google Scholar
• Joyce C, Scallan CD, Mateo R, et al. Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats. Vaccine. 2018 Jul 5;36(29):4265–4277.
   PubMed Web of Science ®Google Scholar
• Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med. 2009 Dec;29(4):725–739.
   PubMed Web of Science ®Google Scholar
• Gomez M, Mufson MA, Dubovsky F, et al. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J. 2009 Jul;28(7):655–658.
   PubMed Web of Science ®Google Scholar
• Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis. 2016 Feb 1;213(3):411–422.
   PubMed Web of Science ®Google Scholar
• Bollani L, Baraldi E, Chirico G, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015 Dec;15(41):97.
   Google Scholar
• Hijano DR, Vu LD, Kauvar LM, et al. Role of type I interferon (IFN) in the Respiratory Syncytial Virus (RSV) immune response and disease severity. Front Immunol. 2019;10:566.
   PubMed Web of Science ®Google Scholar